SCHEMBL5659618

SCHEMBL5659618

NC(=O)N1CCC(N2CCN(C(=O)[CH]Cc3ccc4[nH]nnc4c3)CC2)CC1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACACB O00763 5/20 0.37
ACACA Q13085 5/20 0.37
MAPK10 P53779 1/20 0.33
L3MBTL3 Q96JM7 4/20 0.33
L3MBTL1 Q9Y468 4/20 0.33
MBTD1 Q05BQ5 1/20 0.32
PARP1 P09874 2/20 0.32
PARP2 Q9UGN5 1/20 0.32
ENPP2 Q13822 1/20 0.32
CCR5 P51681 1/20 0.32
HRH3 Q9Y5N1 2/20 0.31
CHRM1 P11229 1/20 0.31
CCR3 P51677 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP3A4 P08684 1/20 0.31
CALCRL Q16602 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5661224 1.00 ACACB (0.37) ACACBACACAMAPK10L3MBTL3L3MBTL1
SCHEMBL5661004 0.91 ADRB1 (0.30)
SCHEMBL5661183 0.83 ACACB (0.42) ACACBACACACYP3A4CALCRL
SCHEMBL5659149 0.83 ACACB (0.42) ACACBACACACYP3A4CALCRL
SCHEMBL5660284 0.83 ACACB (0.34) ACACBACACAL3MBTL3L3MBTL1ENPP2
SCHEMBL5660712 0.83 ACACB (0.34) ACACBACACAL3MBTL3L3MBTL1ENPP2
SCHEMBL3593151 0.82 CNR2 (0.30)
SCHEMBL5660912 0.81 CCR3 (0.47) ACACBACACAPARP1PARP2CCR3
SCHEMBL5660300 0.81 CCR3 (0.47) ACACBACACAPARP1PARP2CCR3
SCHEMBL5661005 0.81 CALCRL (0.44) ACACBACACACYP3A4CALCRL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1722792-A1 SELECTED CGRP-ANTAGONISTS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim International GmbH (DE) 2006-11-22 EP claimed
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 US claimed
WO-2005084672-A1 SELECTED CGRP-ANTAGONISTS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-09-15 WO claimed
US-7205294-B2 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-04-17 US disclosed
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BDKRB1, BDKRB2, CALCRL ACACB 4648/4885ACACA 4522/4885MAPK10 4317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.